AIM: In this prospective observational study, we investigated the efficacy of Stoller afferent nerve stimulation (SANS) in subjects with overactive bladder who failed anticholinergic treatment. METHODS: Thirty-five subjects with overactive bladder who failed therapy with oxybutynin participated in this study. Treatment (n = 35) was given once a week for 30 minutes for overall 10 weeks. In treatment, SANS device (Urosurge) was used. Subjects were assessed with 3-day voiding diary, SEAPI quality of life questionnaires and cystometry before therapy after completion of therapy and at one-year follow-up. RESULTS: In 54% (n = 19) of subjects complete recovery was obtained after treatment. Urgency and SEAPI were reduced significantly whereas urine volume increased significantly (p < 0.01). Complete recovery was maintained in eight of the 19 subjects at one year. CONCLUSIONS: SANS treatment has a short-term positive effect in patients with resistant overactive bladder. However, it was also established that efficacy was maintained at 1 year in only 23% of subjects.
AIM: In this prospective observational study, we investigated the efficacy of Stoller afferent nerve stimulation (SANS) in subjects with overactive bladder who failed anticholinergic treatment. METHODS: Thirty-five subjects with overactive bladder who failed therapy with oxybutynin participated in this study. Treatment (n = 35) was given once a week for 30 minutes for overall 10 weeks. In treatment, SANS device (Urosurge) was used. Subjects were assessed with 3-day voiding diary, SEAPI quality of life questionnaires and cystometry before therapy after completion of therapy and at one-year follow-up. RESULTS: In 54% (n = 19) of subjects complete recovery was obtained after treatment. Urgency and SEAPI were reduced significantly whereas urine volume increased significantly (p < 0.01). Complete recovery was maintained in eight of the 19 subjects at one year. CONCLUSIONS: SANS treatment has a short-term positive effect in patients with resistant overactive bladder. However, it was also established that efficacy was maintained at 1 year in only 23% of subjects.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: J G Blaivas; R A Appell; J A Fantl; G Leach; E J McGuire; N M Resnick; S Raz; A J Wein Journal: Neurourol Urodyn Date: 1997 Impact factor: 2.696
Authors: F Cappellano; P Bertapelle; M Spinelli; F Catanzaro; R Carone; A Zanollo; F De Seta; G Giardiello Journal: J Urol Date: 2001-12 Impact factor: 7.450
Authors: G Amarenco; S Sheikh Ismael; A Even-Schneider; P Raibaut; S Demaille-Wlodyka; B Parratte; J Kerdraon Journal: J Urol Date: 2003-06 Impact factor: 7.450
Authors: Pamela J Levin; Jennifer M Wu; Amie Kawasaki; Alison C Weidner; Cindy L Amundsen Journal: Int Urogynecol J Date: 2012-03-13 Impact factor: 2.894
Authors: Katarina Ivana Tudor; Jai H Seth; Martina D Liechti; Juliana Ochulor; Gwen Gonzales; Collette Haslam; Zoe Fox; Mahreen Pakzad; Jalesh N Panicker Journal: Clin Auton Res Date: 2018-08-03 Impact factor: 4.435
Authors: Fiona Stewart; Luis F Gameiro; Regina El Dib; Monica O Gameiro; Anil Kapoor; Joao L Amaro Journal: Cochrane Database Syst Rev Date: 2016-12-09